UBC® Rapid
For Bladder Cancer detection

Accurate tumor status in moments that matter.
UBC® Rapid is becoming the preferred state of art IVD, enabling both advanced and convenient testing as well as risk stratification.

**Background Bladder Cancer**
Bladder cancer is a common cancer in men and women worldwide and transitional cell carcinoma (TCC) comprises up to 90% of all primary bladder tumors. The risk of developing bladder cancer is three to four times higher in men than in women and it increases with smoking, exposure of industrial chemicals and other carcinogens. At presentation more than 70% are non-muscle invasive bladder cancer, but the recurrence rate is high and therefore many patients progress to muscle invasive bladder cancer or metastatic disease.

The most common methods for detection of bladder cancer and for the assessment of recurrence are cystoscopy and urine cytology. Cystoscopy may cause pain and discomfort in patients and in cases with small tumors or carcinoma in situ, a diagnosis is not readily performed. Urine cytology, a non-invasive urine test, is often used as an adjunct to cystoscopy. However, even if cytology has the advantage of high specificity its sensitivity varies considerably.

To overcome such shortcomings of the existing diagnostic methods for bladder cancer, urine tumor markers are available. One interesting possibility is the measuring of cytokeratin fragment in urine, since elevated amounts of cytokeratin fragments are present in the urine of many individuals with bladder cancer, even at early stages of the disease.

**Cytokeratins**
In conditions of high cell turnover, such as cancer, cytokeratins are released from the epithelial cells and can be detected in blood or urine. At present more than 20 different cytokeratins have been identified, of which cytokeratin 8 and 18 are some of the most abundant in simple epithelial cells. The cytokeratin pattern is usually preserved during the transformation of normal cells into malignant cells.

**UBC® Rapid**
UBC® Rapid is a point-of-care (POC) test that specifically measures soluble fragments of cytokeratin 8 and 18 in urine samples. UBC® Rapid shall be used for quantitative determination in combination with a POC-reader.

**UBC® Rapid works in haematuria**
UBC® Rapid has the advantage of not being sensitive to blood contamination in the urine – haematuria, which is a common symptom of bladder cancer (Lüdecke et al 2012).

The first quantitative POC test platform for Bladder Cancer — UBC® Rapid.
Ritter et al. performed the first clinical evaluation of UBC® Rapid on a POC test platform. The study showed that quantitative results provide higher reproducibility and enable improved risk stratification compared with simple dichotomized POC test results, see table below. The accuracy of the POC test platform is at least equivalent to ELISA in bladder cancer patients (see table below). UBC® Rapid detects more patients with bladder cancer than NMP22® or cytology. Combining cytology with UBC® Rapid yielded a sensitivity of 88% for detection of bladder cancer in high risk patients. UBC® Rapid might be used as an adjunct to cystoscopy and cytology in laboratory independent settings.

Comparison of UBC® Rapid (qualitative determination), UBC® Rapid (quantitative determination) UBC® ELISA, NMP22® BladderChek® and cytology.

<table>
<thead>
<tr>
<th></th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>UBC® Rapid</td>
<td>60.7 %</td>
<td>70.1 %</td>
<td>46.8 %</td>
<td>79.3 %</td>
</tr>
<tr>
<td>UBC® ELISA</td>
<td>48.3 %</td>
<td>71.3 %</td>
<td>42.7 %</td>
<td>75.8 %</td>
</tr>
<tr>
<td>NMP22® BladderChek®</td>
<td>16.4 %</td>
<td>95.3 %</td>
<td>62.5 %</td>
<td>70.5 %</td>
</tr>
<tr>
<td>Cytology</td>
<td>*51.7 %</td>
<td>78.1 %</td>
<td>51.7 %</td>
<td>78.1 %</td>
</tr>
</tbody>
</table>

198 high risk patients (haematuria or irritative voiding syndromes) were included in the study; 61 patients clinically confirmed bladder cancer patients.

High sensitivity for CIS
The performance of the UBC® Rapid POC test platform was further evaluated in a multicenter study (Ecke et al 2015). Subanalysis of patients with cancer in situ demonstrated a very high diagnostic sensitivity (87%) for this aggressive form of bladder cancer that is also difficult to detect with cystoscopy. UBC® Rapid also showed a high diagnostic sensitivity for non-invasive high-grade tumours (71%). It was concluded that UBC® Rapid should be added in the diagnostics for cancer in situ and non-invasive high-grade tumours. (Ecke et al, 2017)
At a glance

**UBC® Rapid - For Bladder Cancer detection**

- The only quantitative POC test platform for urine based detection of bladder cancer.
- Easy and rapid to perform – result within 10 minutes
- Works in haematuria
- **UBC®** also available as ELISA/IRMA

References:


Diagnostic tools for reliable patient management.

**Oncology**

TPS™ UBC® TPAcyk™ MonoTotal™

**Bacteriology**

TUBEX™ TF TUBEX™ WASH BUFFER

IDL Biotech is certified according to ISO 9001:2008 and EN ISO 13485:2012

IDL Biotech AB (publ), P.O Box 11151, SE-161 11 Bromma, Sweden
Phone: +46 8 799 67 50, Fax: +46 8 799 93 20
idlbiotech@idl.se, www.idl.se